Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 75.80% | -63.75% | -413.44% | 223.59% | -194.53% |
| Total Depreciation and Amortization | 6.64% | -11.29% | 1.17% | -31.21% | -68.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.54% | 160.04% | 97.13% | -448.29% | 1,244.61% |
| Change in Net Operating Assets | -518.97% | 148.15% | -77.38% | 30.20% | -33.11% |
| Cash from Operations | -18.16% | -21.11% | 20.46% | 8.08% | 18.78% |
| Capital Expenditure | -228.57% | -642.31% | -1,457.14% | 37.68% | -300.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -109.65% | 359.29% | -198.28% | 50.30% | -- |
| Cash from Investing | -110.12% | 358.58% | -198.57% | 50.29% | 285,414.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 93.02% | -100.00% | 93.75% | -- | -975.00% |
| Issuance of Common Stock | -10.00% | -- | -- | -- | -99.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 26.80% | -1,225.00% | -162.99% | 535,584.21% | -99.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,519.15% | 339.88% | -365.16% | 133.00% | -97.45% |